These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
146 related items for PubMed ID: 2908302
21. Clinical pharmacology of carvedilol in normal volunteers. Cubeddu LX, Fuenmayor N, Varin F, Villagra VG, Colindres RE, Powell JR. Clin Pharmacol Ther; 1987 Jan; 41(1):31-44. PubMed ID: 3802704 [Abstract] [Full Text] [Related]
22. The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Riva E, Mennini T, Latini R. Br J Pharmacol; 1991 Dec; 104(4):823-8. PubMed ID: 1687367 [Abstract] [Full Text] [Related]
23. Oral administration of carvedilol and prazosin inhibits the prostaglandin F2 alpha- and noradrenaline-induced contraction of human hand veins in vivo. Beermann C, Schloos J, Belz GG. Clin Investig; 1992 Dec; 70 Suppl 1():S13-9. PubMed ID: 1317234 [Abstract] [Full Text] [Related]
24. Pre-weaning carvedilol treatment in spontaneously hypertensive rats. Boesen EI, Lambert GW, Anderson WP, Kett MM. Eur J Pharmacol; 2004 Feb 20; 486(2):183-8. PubMed ID: 14975707 [Abstract] [Full Text] [Related]
25. Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation. Ruffolo RR, Sauermelch CF, Willette RN. Eur J Clin Pharmacol; 1990 Feb 20; 38 Suppl 2():S112-4. PubMed ID: 1974499 [Abstract] [Full Text] [Related]
26. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. Tomlinson B, Cronin CJ, Graham BR, Prichard BN. J Cardiovasc Pharmacol; 1987 Feb 20; 10 Suppl 11():S69-75. PubMed ID: 2454372 [Abstract] [Full Text] [Related]
27. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WG, Feuerstein GZ. J Pharmacol Exp Ther; 1996 Nov 20; 279(2):948-55. PubMed ID: 8930204 [Abstract] [Full Text] [Related]
28. Local cutaneous hemodynamic effects of carvedilol and labetalol in the anesthetized rat. Willette RN, Sauermelch CF, Ruffolo RR. Eur J Pharmacol; 1990 Feb 06; 176(2):237-40. PubMed ID: 2311669 [Abstract] [Full Text] [Related]
29. Effect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats. Gellai M, DeWolf R, Ruffolo RR. Pharmacology; 1990 Feb 06; 41(4):200-6. PubMed ID: 2080230 [Abstract] [Full Text] [Related]
30. Opposite influences of hypertension and diabetes mellitus on pressor responses induced by different alpha-adrenoceptor agonists and angiotensin II in pithed rats. Beenen OH, Mathy MJ, Pfaffendorf M, van Zwieten PA. Blood Press; 1996 Jan 06; 5(1):57-63. PubMed ID: 8777475 [Abstract] [Full Text] [Related]
31. Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties. Strein K, Sponer G, Müller-Beckmann B, Bartsch W. J Cardiovasc Pharmacol; 1987 Jan 06; 10 Suppl 11():S33-41. PubMed ID: 2454365 [Abstract] [Full Text] [Related]
32. Low concentrations of angiotensin II unmask vasoconstrictory alpha 2-adrenoceptors in isolated perfused kidneys of spontaneously hypertensive rats. Bohmann C, Rist W, Schollmeyer P, Rump LC. Cardiovasc Res; 1995 Dec 06; 30(6):857-65. PubMed ID: 8746199 [Abstract] [Full Text] [Related]
33. Evaluation of the risk for drug-induced postural hypotension in an experimental model: investigations with carvedilol, prazosin, labetalol, and guanethidine. Bartsch W, Sponer G, Strein K, Böhm E, Hooper RG. J Cardiovasc Pharmacol; 1987 Dec 06; 10 Suppl 11():S49-51. PubMed ID: 2454367 [Abstract] [Full Text] [Related]
34. Adrenergic receptor effects and antihypertensive actions of beta-adrenoceptor-blocking agents with ancillary properties. Imai S, Nakahara H, Nakazawa M, Takeda K. Drugs; 1988 Dec 06; 36 Suppl 6():10-9. PubMed ID: 2908298 [Abstract] [Full Text] [Related]
35. Pharmacological characteristics of the stereoisomers of carvedilol. Bartsch W, Sponer G, Strein K, Müller-Beckmann B, Kling L, Böhm E, Martin U, Borbe HO. Eur J Clin Pharmacol; 1990 Dec 06; 38 Suppl 2():S104-7. PubMed ID: 1974497 [Abstract] [Full Text] [Related]
36. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. Sponer G, Bartsch W, Strein K, Müller-Beckmann B, Böhm E. J Cardiovasc Pharmacol; 1987 Mar 06; 9(3):317-27. PubMed ID: 2437399 [Abstract] [Full Text] [Related]
37. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR. Pharmacology; 1989 Mar 06; 39(5):327-36. PubMed ID: 2575762 [Abstract] [Full Text] [Related]
38. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Wong VY, Laping NJ, Nelson AH, Contino LC, Olson BA, Gygielko E, Campbell WG, Barone F, Brooks DP. Br J Pharmacol; 2001 Nov 06; 134(5):977-84. PubMed ID: 11682445 [Abstract] [Full Text] [Related]
39. Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. Bertera FM, Del Mauro JS, Chiappetta D, Polizio AH, Buontempo F, Taira CA, Höcht C. Naunyn Schmiedebergs Arch Pharmacol; 2012 Mar 06; 385(3):325-35. PubMed ID: 22048841 [Abstract] [Full Text] [Related]
40. The effect of losartan and carvedilol on vasopressor responses to adrenergic agonists and angiotensin II in the systemic circulation of Sprague Dawley rats. Abdulla MH, Sattar MA, Abdullah NA, Khan MA, Anand Swarup KR, Johns EJ. Auton Autacoid Pharmacol; 2011 Mar 06; 31(1-2):13-20. PubMed ID: 21166975 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]